HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target
Moleculin Biotech, Inc. +0.83%
Moleculin Biotech, Inc. MBRX | 2.42 | +0.83% |
HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:
MBRX) with a Buy and maintains $22 price target.
